ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

AI Briefing

• – ReAlta Life Sciences has raised $40 million in funding to advance its pegtarazimod program for Hypoxic Ischemic Encephalopathy.
• – The company plans to use the funding to support the Phase 2 trials of pegtarazimod in HIE.
• – The oversubscribed financing round was led by existing investors.